Advertisement
Surrozen, Inc.

Surrozen, Inc. Fundamental Analysis

SRZNWNASDAQ
HealthcareBiotechnology
$0.02
$0.002(11.17%)
U.S. Market opens in 16h 10m
Advertisement

Surrozen, Inc. Fundamental Analysis

Surrozen, Inc. (SRZNW) shows weak financial fundamentals with a PE ratio of -0.78, profit margin of -45.71%, and ROE of 3.10%. The company generates $0.0B in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

Cash Position61411.06%
PEG Ratio0.01
Current Ratio11.91

Areas of Concern

ROE3.10%
Operating Margin-5.74%
We analyze SRZNW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -3399.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-3399.6/100

We analyze SRZNW's fundamental strength across five key dimensions:

Efficiency Score

Weak

SRZNW struggles to generate sufficient returns from assets.

ROA > 10%
-2.84%

Valuation Score

Excellent

SRZNW trades at attractive valuation levels.

PE < 25
-0.78
PEG Ratio < 2
0.01

Growth Score

Weak

SRZNW faces weak or negative growth trends.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
-1.59%

Financial Health Score

Excellent

SRZNW maintains a strong and stable balance sheet.

Debt/Equity < 1
-0.02
Current Ratio > 1
11.91

Profitability Score

Weak

SRZNW struggles to sustain strong margins.

ROE > 15%
3.10%
Net Margin ≥ 15%
-45.71%
Positive Free Cash Flow
No

Key Financial Metrics

Is SRZNW Expensive or Cheap?

P/E Ratio

SRZNW trades at -0.78 times earnings. This suggests potential undervaluation.

-0.78

PEG Ratio

When adjusting for growth, SRZNW's PEG of 0.01 indicates potential undervaluation.

0.01

Price to Book

The market values Surrozen, Inc. at -0.96 times its book value. This may indicate undervaluation.

-0.96

EV/EBITDA

Enterprise value stands at -2.73 times EBITDA. This is generally considered low.

-2.73

How Well Does SRZNW Make Money?

Net Profit Margin

For every $100 in sales, Surrozen, Inc. keeps $-45.71 as profit after all expenses.

-45.71%

Operating Margin

Core operations generate -5.74 in profit for every $100 in revenue, before interest and taxes.

-5.74%

ROE

Management delivers $3.10 in profit for every $100 of shareholder equity.

3.10%

ROA

Surrozen, Inc. generates $-2.84 in profit for every $100 in assets, demonstrating efficient asset deployment.

-2.84%

Following the Money - Real Cash Generation

Operating Cash Flow

Surrozen, Inc. generates limited operating cash flow of $-22.85M, signaling weaker underlying cash strength.

$-22.85M

Free Cash Flow

Surrozen, Inc. generates weak or negative free cash flow of $-23.00M, restricting financial flexibility.

$-23.00M

FCF Per Share

Each share generates $-3.08 in free cash annually.

$-3.08

FCF Yield

SRZNW converts -18.29% of its market value into free cash.

-18.29%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.78

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.009

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.96

vs 25 benchmark

P/S Ratio

Price to sales ratio

24.35

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

11.91

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

3.10

vs 25 benchmark

ROA

Return on assets percentage

-2.84

vs 25 benchmark

ROCE

Return on capital employed

-0.39

vs 25 benchmark

How SRZNW Stacks Against Its Sector Peers

MetricSRZNW ValueSector AveragePerformance
P/E Ratio-0.7829.01 Better (Cheaper)
ROE309.79%730.00% Weak
Net Margin-4571.14%-53564.00% (disorted) Weak
Debt/Equity-0.020.39 Strong (Low Leverage)
Current Ratio11.914.47 Strong Liquidity
ROA-283.79%-18932.00% (disorted) Weak

SRZNW outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Surrozen, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

65.01%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

88.77%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ